From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

UC Irvine to Develop Q Fever Vaccine

by Global Biodefense Staff
March 28, 2016
Q Fever - Coxiella Burnetii

Q Fever - Coxiella BurnetiiThe Defense Threat Reduction Agency (DTRA) has awarded a University of California, Irvine scientific team an $8 million contract to help develop a new vaccine for Q fever.

Caused by the Coxiella burnetii bacterium, Q fever is a highly infectious agent common among livestock. It has a history of being aerosolized for use in biological warfare and is considered a potential bioterrorism weapon.

Q fever is also a public health threat; a 2007-10 outbreak in the Netherlands affected thousands of people. Symptoms include high fever, nausea, severe headache and abdominal pain. It is rarely fatal.

The development effort is led by infectious diseases researchers Philip Felgner and Aaron Esser-Kahn.

“The current vaccine for Q fever is effective but has severe side effects that limit its widespread use,” said Felgner, an adjunct professor of medicine at UC Irvine. “It’s a high priority that this vaccine be administered to members of the armed forces. Consequently, the military is interested in developing an alternative protective vaccine that’s safer and does not cause adverse reactions.”

Felgner will use an approach he pioneered at UC Irvine to create whole proteome microarrays to discover immune response-activating antigen proteins that may be effective as a vaccine. Additionally, he’ll collaborate with Esser-Kahn, assistant professor of chemistry, whose group will develop synthetic agents that can boost and control the immune response to these proteins.

Felgner said this dual method may be applicable in creating more vaccines important to the military and general public health, adding that this is an opportunity for the Department of Defense to test these methods for their potential use against other infectious diseases.

After identifying the target proteins, Felgner will work with the U.S. Army Medical Research Institute of Infectious Diseases at Fort Detrick in Maryland on next-stage animal studies of a candidate vaccine.

The project is a successful outgrowth of the Pacific Southwest Regional Center of Excellence at UC Irvine, one of only 11 National Institutes of Health-funded research sites dedicated to countering threats from bioterrorism agents and emerging infectious diseases. UC Irvine received $85 million for this effort, which was led by Dr. Alan Barbour, professor of microbiology & molecular genetics. The federal program ended in 2015.

Image courtesy of NIAID, adapted.

From Our Partners
Tags: AwardsBioterrorismQ FeverSynthetic BiologyVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies
Biosecurity

Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies

June 14, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC